Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: dexlansoprazole Clear all
Completed Phase 3 Interventional Results available

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

NCT00255151
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
100
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

NCT00321737
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
80
States / cities
Huntsville, Alabama • Tuscon, Arizona • Anaheim, California + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 27, 2026, 10:14 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin

NCT02387203
View directory record Official record
Conditions
Pseudomyxoma Peritonei, Appendiceal Neoplasms
Interventions
PrevPac (Prevacid, Amoxicillin, Clarithromycin)
Drug
Lead sponsor
Mercy Medical Center
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

NCT00942175
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel

NCT01147588
View directory record Official record
Conditions
Healthy
Interventions
lansoprazole, omeprazole, esomeprazole, clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Sep 27, 2026, 10:14 AM EDT
Terminated No phase listed Observational

Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD

NCT00624546
View directory record Official record
Conditions
GERD, Gastroesophageal Reflux
Interventions
Prevacid Solutabs, Antireflux surgery
Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 74 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2015 · Synced Sep 27, 2026, 10:14 AM EDT
Terminated Not applicable Interventional

Quantifying Effects of Treatment of Pediatric Dysphonia

NCT00237679
View directory record Official record
Conditions
Voice Disorders, Gastroesophageal Reflux
Interventions
Neuromuscular Electrical Stimulation, Unstimulated
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
6 Years to 11 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 27, 2026, 10:14 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Comparison of Voice Therapy and Antireflex Therapy in LPR

NCT02530879
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Omeprazole, Lansoprazole, Esomeprazole, Rantidine, Voice therapy, Combination of anti-reflux medication and voice therapy
Drug · Behavioral · Other
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Proton Pump Inhibitors on Endothelial Function

NCT02022280
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Lansoprazole, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Phase 4 Interventional Results available

Lansoprazole to Treat Children With Asthma

NCT00442013
View directory record Official record
Conditions
Asthma
Interventions
Lansoprazole, Matching placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 17 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251719
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
100
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes

NCT01155284
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sitagliptin and Lansoprazole, Placebo
Drug
Lead sponsor
Sanford Health
Other
Eligibility
11 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
3
States / cities
San Diego, California • Saint Paul, Minnesota • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 27, 2026, 10:14 AM EDT
Not listed Phase 4 Interventional

Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy

NCT01328652
View directory record Official record
Conditions
Laryngopharyngeal Reflux, Hypertrophy of Lingual Tonsil
Interventions
dexlansoprazole
Drug
Lead sponsor
Advanced Center for Specialty Care
Other
Eligibility
18 Years to 59 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 4, 2011 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Phase 3 Interventional

The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux

NCT00324974
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Lansoprazole microgranules suspension, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Month to 11 Months
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
9
States / cities
Tampa, Florida • Park Ridge, Illinois • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2010 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Lansoprazole 30 mg DR Capsule Fasting Study

NCT01045967
View directory record Official record
Conditions
Healthy
Interventions
Lansoprazole, Prevacid®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Lansoprazole in Chronic Post Nasal Drip

NCT00335283
View directory record Official record
Conditions
Larynx Disease
Interventions
Lansoprazole Tablet, PH and impedence testing, manometry, lansoprazole, placebo
Drug · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Not applicable Interventional

Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers

NCT00573924
View directory record Official record
Conditions
Peptic Ulcer Hemorrhage
Interventions
Proton pump inhibitor (lansoprazole)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Sep 27, 2026, 10:14 AM EDT
Withdrawn Not applicable Interventional

Proton Pump Inhibitor Therapy for Mild to Moderate Obstructive Sleep Apnea

NCT00211614
View directory record Official record
Conditions
Obstructive Sleep Apnea, Gastroesophageal Reflux
Interventions
Lansoprazole
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Phase 4 Interventional

Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer

NCT00239551
View directory record Official record
Conditions
Stomach Ulcer
Interventions
Prevacid
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Early Phase 1 Interventional

Effectiveness of Physiologic Testing in PPI Non-Responders

NCT03202537
View directory record Official record
Conditions
Gastro Esophageal Reflux
Interventions
dexlansoprazole
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets

NCT02096458
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
25 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Phase 4 Interventional

An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

NCT00352261
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Esomeprazole, Lansoprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
Phoenix, Arizona • Tucson, Arizona • North Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Sep 27, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease

NCT00847210
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole MR
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Anaheim, California • Cypress, California • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 27, 2026, 10:14 AM EDT